文献速递消化系统肿瘤

PRODIGE 29-UCGI 26(NEOPAN):比较FOLFIRINOX方案与吉西他滨治疗局部晚期胰腺癌的III期随机试验

PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma.
PubMed 文献 · J Clin Oncol · 2025-05-16

该III期随机试验纳入171例不可手术的局部晚期胰腺癌患者,随机接受FOLFIRINOX或吉西他滨治疗6个月。FOLFIRINOX组中位无进展生存期为9.7个月,吉西他滨组为7.7个月(HR 0.7,P=0.04);两组中位总生存期分别为15.7个月和15.4个月(HR 1.02,P=0.95),无显著差异。

要点

  • FOLFIRINOX较吉西他滨显著改善局部晚期胰腺癌的无进展生存期(HR 0.7,P=0.04)。
  • 两组总生存期无显著差异(HR 1.02,P=0.95)。
  • FOLFIRINOX在局部晚期胰腺癌中耐受性良好。

核心结论

  • FOLFIRINOX较吉西他滨显著改善局部晚期胰腺癌的无进展生存期,且耐受性良好,但两组总生存期无显著差异。

研究设计与样本

  • III期随机对照试验,纳入171例组织学证实、不适合手术的局部晚期胰腺癌患者,ECOG WHO体能状态评分≤1,按中心、肿瘤部位、体能状态和年龄分层,随机接受FOLFIRINOX或吉西他滨治疗6个月。
  • 主要终点为无进展生存期,次要终点包括总生存期、治疗失败时间、生活质量和安全性;需170例患者(142个事件)以80%把握度检测无进展生存期延长3个月(log-rank检验,双侧α=5%)。

主要发现

  • 中位随访59.6个月(95%CI 42.3至未达到),观察到168个事件;FOLFIRINOX组中位无进展生存期9.7个月(95%CI 7.0至11.7),吉西他滨组7.7个月(95%CI 6.2至9.2),HR 0.7(95%CI 0.5至1.0),P=0.04。
  • FOLFIRINOX组中位总生存期15.7个月(95%CI 11.9至20.4),吉西他滨组15.4个月(95%CI 11.7至18.6),HR 1.02(95%CI 0.73至1.43),P=0.95。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: More than 30% of patients with pancreatic cancer are unresectable because of the local extension with a median overall survival (OS) of <1 year. Combination of fluorouracil (FU), oxaliplatin, and irinotecan (FOLFIRINOX) is superior to gemcitabine in the treatment of metastatic pancreatic cancer, but standard of care remains gemcitabine in locally advanced pancreatic cancer (LAPC). METHODS: Patients with histologically proven LAPC not suitable for surgery, Eastern Cooperative Oncology Group WHO performance status (PS) ≤1 were eligible. Random assignment was stratified by center, tumor localization (pancreas head yes/no), WHO PS (0 v 1), and age (≤60 years v >60 years). Patients received FOLFIRINOX or gemcitabine for 6 months. The primary end point was progression-free survival (PFS). Main secondary end points were OS, time to treatment failure, quality of life, and safety. One hundred seventy patients (142 events) were needed to detect an increase of 3 months in PFS with 80% power (log-rank test, 5% two-sided α). RESULTS: One hundred seventy one patients age 35-84 years were included and followed for a maximum of 5 years. With a median follow-up of 59.6 months (95% CI, 42.3 to not reached), 168 events were observed and the median PFS was 9.7 months (95% CI, 7.0 to 11.7) with FOLFIRINOX versus 7.7 months (95% CI, 6.2 to 9.2) with gemcitabine, hazard ratio (HR), 0.7 (95% CI, 0.5 to 1.0), P = .04. The median OS was 15.7 months (95% CI, 11.9 to 20.4) in the FOLFIRINOX group versus 15.4 months (95% CI, 11.7 to 18.6) in the gemcitabine group, HR, 1.02 (95% CI, 0.73 to 1.43), P = .95. CONCLUSION: Results confirm that FOLFIRINOX improves PFS significantly compared with gemcitabine and is well tolerated in LAPC. No significant difference in OS was observed between both groups.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Ducreux M, Desgrippes R, Rinaldi Y, et al. PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma. J Clin Oncol. 2025. PMID: 40378359. doi:10.1200/JCO-24-02210

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。